AKT1 and ovarian carcinoma: Thus, targeting the PI3K-AKT-mTOR, LKB1-AMPK-mTOR, MAPK, and other signal pathways has become the direction of ovarian cancer treatment (Mabuchi et al., 2015; Peng et al., 2021; Takahashi et al., 2021; Blagden, 2022).